21. April 2020

Lunaphore Technologies receives additional CHF 2.000.000 in Series C2 financing, bringing total Series C round to CHF 25.000.000

€ 2.000.000
Series C
Written by

LAUSANNE, Switzerland – April 21, 2020 – 11:30 am (CET) – Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next- generation equipment for cancer research and tissue diagnostics, announces the second closing of its Series C round totaling CHF 25M.

The CHF 2M Series C2 financing was provided by the Swiss Entrepreneurs Fund, who invested a total of CHF 5M in the company. The fund is linked to the Swiss Entrepreneurs Foundation, whose main focus is to invest in Swiss start-ups and SMEs in the growth phase (internationalization) with the goal of bridging the financing gap in Swiss innovation.

Didier Denat, Member of the Decision Committee for direct investments of the Swiss Entrepreneurs Fund and Head of Corporate Banking at Credit Suisse (Switzerland) Ltd. said: “With its outstanding management team and technological USPs, Lunaphore Technologies is able to show significant market traction, combined with a high degree of customer satisfaction. We are fully convinced in both the business model and strategy of Lunaphore Technologies and we are happy to contribute in taking the company to the next level.”

The proceeds of the overall CHF 25M Series C closing, with the first closing announced on February 6, 2020 and led by the Japanese strategic investor PHC Holdings Corporation (PHCHD), will be dedicated to market and product expansion, including a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.

“We are very happy to add the Swiss Entrepreneurs Fund, which focuses on high- growth companies with global ambitions, to our investors’ base. Together with the strategic investment from PHCHD that we recently closed, Lunaphore is now backed by very strong institutions to achieve its vision.”